Risk factors & contraindications | Pre intervention (nā=ā150) | Post intervention (nā=ā150) | P Value |
---|---|---|---|
High-risk of VTE | 126 (84) | 116 (77) | 0.14^ |
Risk factors | Ā | Ā | Ā |
āāāĀ Ischaemic stroke | 7 (4.7) | 3 (2) | 0.19^ |
āāāĀ History of VTE | 15 (10) | 18 (12) | 0.58^ |
āāāĀ Active cancer | 4 (2.7) | 4 (2.7) | 1.0^ |
āāāĀ Decompensated heart failure | 42 (28) | 29 (19) | 0.7^ |
āāāĀ Acute on chronic lung disease | 10 (6.7) | 10 (6.7) | 1.0^ |
āāāĀ Ageā>ā60Ā years and immobile | 107 (71) | 108 (72) | 0.89^ |
āāāĀ Acute inflammatory disease | 6 (4) | 1 (0.7) | 0.5^ |
āāāĀ Multiple additional risk factors | 21 (14) | 10 (6.7) | 0.33^ |
Additional risk factors | Ā | Ā | Ā |
āāāĀ Immobility (<60Ā years) | 1 (0.7) | 1 (0.7) | 0.98^ |
āāāĀ Familial history of VTE | 1 (0.7) | 0 (0) | 0.31^ |
āāāĀ Oestrogen therapy | 2 (1.4) | 1 (0.7) | 0.55^ |
āāāĀ Obesity | 10 (6.8) | 7 (4.7) | 0.43^ |
āāāĀ Thrombophilia | 1 (0.7) | 0 (0) | 0.313^ |
āāāĀ Active inflammation | 6 (4.1) | 2 (1.4) | 0.09^ |
Contraindications | 48 (32) | 49 (32.7) | 0.15^ |
āāāĀ Active bleeding | 5 (3.3) | 5 (3.3) | 1.0^ |
āāāĀ High risk of bleeding | 5 (3.3) | 7 (4.7) | 0.55^ |
āāāĀ Severe hepatic disease | 1 (0.7) | 0 | 0.31^ |
āāāĀ Heparin induced thrombocytopenia | 0 (0) | 0 (0) | Ā |
āāāĀ Current anticoagulation | 41 (27.3) | 38 (25.3) | 0.69^ |
āāāĀ Other contraindication | 0 (0) | 2 (1.3) | 0.15^ |